Introduction Type 2 diabetes mellitus (T2DM) is a substantial health problem worldwide. Prediabetic state is associated with increased risk for the development of diabetes. There are various pharmacologic therapies for diabetes prevention. Of those, most are being compared with placebo instead of active agents. The relative effects and safety of different pharmacologic interventions still remains uncertainty. To address this gap, we will conduct a systematic review and network meta-analysis to evaluate comparative efficacy and safety of pharmacologic therapies for T2DM prevention in patients with prediabetes to generate reliable evidence. Methods and analysis PubMed, the Cochrane library, and EMBASE will be utilized to search for relevant RCTs of pharmacologic therapies for diabetes prevention in participants with prediabetes from inception until December 2018. Two reviewers working independently will screen titles, abstracts, and full papers. Data extraction will also be completed by two independent authors. Primary outcome will be incidence of T2DM in patients with prediabetes at baseline. Secondary outcomes will include achievement of normoglycaemia, all-cause mortality, cardiovascular mortality, and hypoglycaemic event. Pairwise meta-analysis and network meta-analysis will be conducted for each outcome using a random-effects model within a frequentist approach. To evaluate the robustness of our findings, subgroup analyses and sensitivity analyses will also be performed. The comparison-adjusted funnel plot will be used to assess publication bias. The overall quality of evidence of estimates will be rated with the recommendations assessment, development and evaluation (GRADE) framework. Data analysis will be conducted using Stata V.14.0. Ethics and dissemination Ethics approval is not required. We plan to submit results of this study to a peer-review journal. PROSPERO registration number CRD42019119157.
of trials comparing two interventions directly while a network meta-analysis (NMA) method is able to combine direct and indirect evidence and assess comparative efficacy and safety of various interventions. [12] [13] [14] Therefore, to bridge this knowledge gap, we plan to conduct a network meta-analysis to assess comparative effectiveness and safety of several medications for preventing T2DM in participants with prediabetes, which may provide beneficial information for clinical decision-making and further clinical trials.
METHODS

Study design and registration
This systematic review protocol is reported in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines. 15, 16 This study will be performed in accordance with PRISMA extension statements for network meta-analysis. 12 Eligibility criteria Population Adults (older than 18 years) who have prediabetes will be eligible for inclusion. In this study, prediabetic state involves separate impaired fasting glucose (IFG), separate impaired glucose tolerance (IGT), separate elevated glycosylated haemoglobin A1c (HbA1c) or combinations thereof. Diagnostic criteria for prediabetes should be established and described in eligible trials.
Intervention and comparator
This study will investigate comparisons of pharmacological interventions versus another active agent, lifestyle interventions (diet, exercise, or both), placebo or no intervention. Pharmacological therapies include alpha-glucosidase inhibitors, sulphonylureas, meglitinide analogues, dipeptidyl-peptidase (DPP)-4 inhibitors, glucagon-like peptide (GLP)-1 analogues, biguanides, thiazolidinediones, alone or in combination.
Outcomes
Primary outcome will be incidence of T2DM in patients with prediabetes at baseline. Secondary outcomes will include achievement of normoglycaemia, all-cause mortality, cardiovascular mortality, and hypoglycaemic event. Classification and definition of T2DM could be based on any recognised standard diagnosis criteria (ie, the American Diabetes Association guidelines).
Type of studies
All randomised controlled trials (RCTs) comparing pharmacological agents with other drugs, lifestyle interventions, placebo or no intervention for T2DM prevention in patients with prediabetes will be included in this study. Duration of intervention has to be with a minimum duration of 12 weeks.
Search strategy
Various databases will be utilized to search for RCTs of pharmacologic therapies for preventing diabetes among patients with prediabetes from inception date of databases until December 2018. The databases will include PubMed, Embase, and the Cochrane Library. In addition, the language of publication will be limited to English. Any potentially-relevant article will be retrieved for 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 review. Details of search strategy of PubMed database is shown in supplemental material. The literature search will be conducted using the following keywords: alpha-glucosidase inhibitors, sulphonylureas, glinide, dipeptidyl-peptidase (DPP)-4 inhibitors, glucagon-like peptide (GLP)-1 analogues, biguanides, thiazolidinediones, diabetes, T2DM, prediabetes, prediabetic state, glucose intolerance, impaired glucose, diabetic, dysglycaemia, hyperglycaemia, conversion, delay, and prevent. Moreover, all drug names in each drug class will be included in key search terms, for instance, acarbose, voglibose, metformin, alogliptin, saxagliptin, liraglutide, and albiglutide. To identify other eligible studies, reference lists of relevant publications (including trials, reviews, and meta-analyses) will be reviewed for a manual search.
Selection of studies
In accordance with the prespecified inclusion criteria, two reviewers working independently will evaluate all titles and abstracts to eliminate papers deemed irrelevant. The remaining articles will be included in the further assessment. Reviewers will scrutinize full text for each potentially-relevant article. The study identification and exclusion process will be depicted using the PRISMA flow diagram. Discrepancies in study selection will be resolved by negotiation.
Data collection process
Two independent reviewers will use a standardized data form to extract trial information. All disagreements will be settled via discussion with the third reviewer. The data extracted will be as follows: ► Patient characteristics (age, gender, race, weight and glycemic parameters). ► trial characteristics (author, publication year, study design, country setting, and funding information). ►Details of intervention and control (dosage, frequency, and treatment duration). ►Outcome data for all endpoints of interest.
Assessment of methodological quality
The Cochrane risk of bias assessment tool will be used to assess risk of bias for individual studies. The method includes following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. 17 Each item will be classified into one of three categories as follows: unclear, high or low risk. All discrepancies in quality assessment will be resolved after mutual agreement and discussion.
Data synthesis and statistical analysis
Initially, we will use a random-effects approach to pool effect estimates for all treatment comparisons in conventional pairwise meta-analyses. For categorical outcomes, the pooled estimates as risk ratios (RRs) with 95% confidence intervals (CIs) will be reported. Continuous data will be reported as mean differences (MDs) with their respective 95% CIs. Statistical heterogeneity across trials will be examined using the I 2 statistic. An I 2 statistic of 75%, 50%, or 25% indicates high, moderate, or low heterogeneity, separately. 18 Then, network meta-analyses will be carried out in a frequentist environment. Local inconsistency between direct and indirect evidence within each closed loop will be assessed using a node-splitting test. 19, 20 In addition, a "design-by-treatment" model will be applied to evaluate the assumption of consistency in the whole network. 19 We will generate the surface under the cumulative ranking curve (SUCRA) to assess probabilities of interventions in superiority regarding efficacy and safety outcomes, with higher SUCRA values indicating better effects or safety. 21 The level of significance will be set at an alpha of 0.05. All analyses will be performed with Stata version 14.0 (StataCorp, College Station, TX).
Sensitivity and subgroup analyses
We will perform additional sensitivity analyses. Where possible, analyses will be stratified by age (18-64 years and at least 65 years), gender, ethnicity, and BMI (25-29.9 kg/m 2 and ≥30 kg/m 2 ). Moreover, we will also perform subgroup analyses according to diagnostic criteria (IFG, IGT, and HbA1c).
Publication bias
We will employ the comparison-adjusted funnel plot to assess small study effects including publication bias at the network level. 22
Quality of evidence
The quality of evidence of estimates derived from NMA will be rated using the recommendations assessment, development and evaluation (GRADE) framework. The GRADE approach characterises the quality of evidence according to publication bias, study limitations, inconsistency, imprecision, and indirectness. 23 Evidence of efficacy outcomes will be rated from high quality to very low quality.
Patient and public involvement
No patients or public will participate in the study.
Ethics and dissemination
Since confidential patient data will not be involved in this study, formal ethics approval is not required. The framework of the PRISMA statements for NMA will be applied to guide review authors to perform this study. The results will be disseminated by a peer-reviewed publication.
DISCUSSION
This study is a comprehensive NMA comparing and ranking a variety of pharmacological interventions for preventing T2DM in patients at high risk for the development of T2DM. Our study will provide a summary of the best available evidence concerning pharmacological therapies for T2DM prevention in patients with prediabetic state, benefitting for clinicians, guideline-makers, and policy-makers to generate higher quality recommendations for these patients. Although a relevant NMA 24 published, the study was based on clinical trials before 2014. Additionally, included pharmacological interventions in the study were limited, dipeptidyl-peptidase (DPP)-4 inhibitors, glucagon-like peptide (GLP)-1 analogues, and some other glucose-lowering drugs that have been tested by later trials clinically were not involved. It is essential to contain these commonly prescribed agents in multiple comparisons of medications for the prevention of T2DM. Moreover, the definition of adults at high risk for T2DM was based on 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   6 IFG and IGT, excluding people identified by HbA1c. Importantly, HbA1c is a biomarker of long-term glycemic control when compared IFG and IGT, representing average blood glucose levels during the preceding two to three months. 25 Several strengths can be foreseen of this review, but our network meta-analysis may have some possible limitations. The different frequencies, dosage, and routes of administration of pharmacological therapies may result in considerable heterogeneity. Differences in inclusion criteria of participants and definition of end-point events may influence the quality of evidence.
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Strengths and limitations of this study
► This is a comprehensive systematic review and network meta-analysis to evaluate the effectiveness and safety of various glucose-lowering medications on diabetes prevention among people with prediabetic state. ► Where possible, a NMA will combine direct evidence with indirect evidence, allowing comparisons of treatments without being compared to each other head-to-head in clinical trials. ► This research will generate clinically useful evidence to benefit patients, clinicians, and guideline-makers. 
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic and complex disease, related to insulin secretory defects frequently on the background of insulin resistance; the progression of the disease is associated with genetic factors, metabolic stress, and inflammation. 1 The global prevalence of T2DM was estimated to be 463 million people in 2017. 2 People with T2DM are at elevated risk for chronic kidney disease, heart failure, atherosclerotic cardiovascular disease, polyneuropathy, cognitive impairment, anxiety disorder, and depression. [3] [4] [5] The term prediabetes is used to describe a blood glucose level higher than the normal range but below the cut-off value for T2DM. 6 Different glycemic measurements to define the prediabetic stage exist, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and elevated glycosylated haemoglobin A1c (HbA1c). 1 According to the standards of medical care in diabetes of the American Diabetes Association (ADA), prediabetes is defined as a fasting plasma glucose of at least 5.6 mmol/L but lower than 6.9 mmol/L, a HbA1c of 5.7-6.4%, or IGT (a 2-hour plasma glucose value of 7.8-11.1 mmol/L during oral glucose tolerance test). 1 These measurements are considered to predict a different risk spectrum for the progression of prediabetes to diabetes. The International Diabetes Federation (IDF) estimated that, in 2017, approximately 352 million persons globally had IGT, which is projected to exceed half a billion people before 2045. 7 Hyperglycemia is a well described risk factor for all-cause mortality, total number of all-age deaths attributable to high fasting plasma was 6.5 million people in 2017, 8 with T2DM accounting for 1 million deaths. 9 Moreover, the economic burden of diabetes is large; in 2017, the ADA estimated the total economic costs attributable to diabetes in the U.S. to be $327 billion. 10, 11 Diabetic patients incurred average medical expenditures of $16,750 yearly, with diabetes accounting for $9,600. 11 Thus, there is an urgent need to address huge burden of this worldwide disease with a growing number of suffers. Early interventions for preventing type 2 diabetes are warranted. 10 Persons diagnosed with prediabetes are thought to be at increased risk for developing T2DM, the estimated incidence rate of diabetes among people defined as "prediabetic stage" by measurements of IFG, IGT, or HbA1c in the following 10 years exceeds one-third. 12 These people are ideal candidates for diabetes prevention efforts.
To prevent the progression of prediabetes to T2DM, an intensive behavioral lifestyle intervention program is recommended in the ADA guidelines, including individualized medical nutrition therapy, physical activity, and no tobacco use. 13 Besides lifestyle modification, a variety of anti-diabetic agents have been investigated in clinical trials for diabetes prevention, including insulin secretagogues, glucagon-like peptide (GLP)-1 analogues, alpha-glucosidase inhibitors, dipeptidyl-peptidase (DPP)-4 inhibitors, biguanides, and thiazolidinediones. These pharmacologic approaches with intrinsic glucose-lowering activity (e.g., improve the insulin resistance and preserve pancreatic β -cell function) are recommended for glycemic treatment in patients with T2DM in the ADA guidelines. 14 Of these pharmacologic medications, only metformin therapy for diabetes prevention is recommended as an option for patients with prediabetes. 13 However, to date, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 whether other glucose-lowering agents should be considered in those patients or not has not yet to be clarified clearly, even though some findings of recent studies have demonstrated that these pharmacological agents could also exert benefits to prevent or delay the progression to T2DM. In addition, head-to-head comparisons of different anti-diabetic agents have rarely been performed by previous clinical trials. Evidence regarding the overall and comparative efficacy of these anti-hyperglycemia agents for T2DM prevention is limited, while it is important for clinical decision-making. Conventional pairwise meta-analyses are limited to pool the results of trials comparing two interventions directly while a network meta-analysis (NMA) method is able to combine direct and indirect evidence and assess comparative efficacy and safety of various interventions. [15] [16] [17] Therefore, to bridge this knowledge gap, we plan to conduct the systematic review and NMA to assess comparative effects and safety of various anti-diabetic medications in preventing T2DM in patients with prediabetes, which may provide beneficial information for clinical decision-making and further clinical trials.
METHODS
Study design and registration
This systematic review protocol is reported in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines. 18, 19 This study will be performed in accordance with the PRISMA extension statements for NMA. 15 
Eligibility criteria Population
Adults (older than 18 years) who have prediabetes will be eligible for inclusion. In this study, prediabetic state involves separate IFG, separate IGT, separate elevated HbA1c or combinations thereof. Diagnostic criteria for prediabetes should be established and described in eligible trials.
Intervention and comparator
This study will investigate comparisons of anti-diabetic drugs versus another anti-diabetic agent, lifestyle interventions (diet, exercise, or both), placebo or no intervention. Anti-diabetic agents include alpha-glucosidase inhibitors (e.g., acarbose and voglibose), sulphonylureas (e.g., glipizide and glimepiride), meglitinide analogues (e.g., nateglinide), dipeptidyl-peptidase (DPP)-4 inhibitors (e.g., linagliptin and vildagliptin), glucagon-like peptide (GLP)-1 analogues (e.g., exenatide and liraglutide), biguanides (e.g., metformin), thiazolidinediones (e.g., rosiglitazone and pioglitazone), alone or in combination. In addition, studies using vitamins, traditional Chinese medicines, or alternative/herbal supplements will be excluded.
Outcomes
The primary outcome will be the incidence of T2DM in patients with prediabetes at baseline. Secondary outcomes will include the achievement of normoglycemia, all-cause mortality, cardiovascular mortality, and hypoglycemic event. Classification and definition of T2DM could be based on any recognized standard diagnosis criteria (e.g., the ADA guidelines).
Type of studies
All randomized controlled trials (RCTs) comparing anti-diabetic drugs with another anti-diabetic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   4 agent, lifestyle interventions, placebo or no intervention for T2DM prevention in patients with prediabetes will be included in this study. Duration of intervention has to be with a minimum of 12 weeks.
Search strategy
Several databases will be searched from inception to December 2019 for RCTs that investigated anti-diabetic agents for prevention of diabetes among patients with prediabetes. The databases will include PubMed, Embase, and the Cochrane Library. In addition, the language of publication will be limited to English. Any potentially-relevant article will be retrieved for review. Details of search strategy of PubMed database are shown in the supplemental material. The literature search will be conducted using the following keywords: alpha-glucosidase inhibitors, sulphonylureas, glinides, dipeptidyl-peptidase (DPP)-4 inhibitors, glucagon-like peptide (GLP)-1 analogues, biguanides, thiazolidinediones, diabetes, T2DM, prediabetes, prediabetic state, glucose intolerance, impaired glucose, conversion, delay, and prevent. Moreover, all drug names in each drug class will be included in key search terms, for instance, acarbose, voglibose, metformin, glipizide, glimepiride, linagliptin, vildagliptin, nateglinide, liraglutide, exenatide, rosiglitazone, and pioglitazone. To identify other eligible studies, reference lists of relevant publications (including trials, reviews, and meta-analyses) will be reviewed for a manual search.
Selection of studies
In accordance with the prespecified inclusion criteria, two reviewers working independently will evaluate all titles and abstracts to eliminate papers that were deemed irrelevant. The remaining articles will be included in the further assessment. Reviewers will scrutinize full text for each potentially-relevant article. The study identification and exclusion process will be depicted using the PRISMA flow diagram. Discrepancies in study selection will be resolved by negotiation.
Data collection process
Two independent reviewers will use a standardized data form to extract trial information. All disagreements will be settled via discussion with the third reviewer. The data extracted will be as follows: ► Patient characteristics (age, gender, race, and glycemic parameters). ► Trial characteristics (author, year of publication, study design, number of participants, country setting, and funding information). ► Details of intervention and control (dosage, frequency, and treatment duration). ► Data on the outcomes mentioned above.
Assessment of methodological quality
The Cochrane risk of bias assessment tool will be used to assess risk of bias for individual studies. This method includes the following seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. 20 Each item will be classified into one of three categories as follows: unclear, high, or low risk. All discrepancies in quality assessment will be resolved after mutual agreement and discussion. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Data synthesis and statistical analysis
Initially, we will use a random-effects approach to pool effect estimates for all treatment comparisons in conventional pairwise meta-analyses. For categorical outcomes, the pooled estimates as risk ratios (RRs) with 95% confidence intervals (CIs) will be reported. When data is available, to observe whether the effects of medications on diabetes prevention remain after intervention withdrawn, the pooled RRs for diabetes of the intervention and wash-out or follow-up periods, respectively, will be estimated. Continuous data will be reported as mean differences (MDs) with their respective 95% CIs. Statistical heterogeneity across trials will be examined using the I 2 statistic. The I 2 statistic of 75%, 50%, or 25% indicates high, moderate, or low heterogeneity, separately. 21 Then, a NMA will be conducted with a frequentist random-effects model. Local inconsistency between direct and indirect evidence within each closed loop will be assessed using a node-splitting test. 22, 23 In addition, a "design-by-treatment" model will be applied to evaluate the assumption of consistency in the whole network. 22 We will generate the surface under the cumulative ranking curve (SUCRA) to assess probabilities of interventions in superiority regarding efficacy and safety outcomes, with higher SUCRA values indicating better effects or safety. 24 The level of significance will be set at an alpha of 0.05. All analyses will be performed with Stata version 14.0 (StataCorp, College Station, TX).
Subgroup analyses
Where possible, analyses will be stratified by age (18-45 years and at least 45 years), gender, ethnicity, and BMI (25-29.9 kg/m 2 and ≥30 kg/m 2 ). Moreover, we will also perform subgroup analyses according to diagnostic criteria of prediabetes (IFG, IGT, and HbA1c).
Publication bias
We will use the comparison-adjusted funnel plot to assess small study effects including publication bias at the network level. 25
Quality of evidence
The quality of evidence of estimates derived from this study will be rated using the grading of recommendations assessment, development and evaluation (GRADE) framework. The GRADE approach characterises the quality of evidence according to publication bias, study limitations, inconsistency, imprecision, and indirectness. 26 Evidence of efficacy outcomes will be rated from high quality to very low quality.
Patient and public involvement
Ethics and dissemination
DISCUSSION
This study is a comprehensive systematic review and NMA to compare and rank a variety of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 anti-diabetic agents for preventing the development of T2DM in patients with prediabetes. Our study will provide a summary of available evidence concerning various anti-hyperglycemia agents for T2DM prevention in patients with prediabetic state, benefiting for clinicians and guideline-makers to generate high quality recommendations for these patients. Although a relevant NMA 27 published, the study was based on clinical trials before 2014. Additionally, included types anti-diabetic agents in the study were limited, dipeptidyl-peptidase (DPP)-4 inhibitors, glucagon-like peptide (GLP)-1 analogues, and some other glucose-lowering drugs that have been tested by later trials clinically were not involved. It is essential to contain these commonly prescribed medications in multiple comparisons of glucose-lowering agents for the prevention of T2DM. Moreover, the definition of adults at high risk for T2DM was based on IFG and IGT, excluding people identified by HbA1c. Importantly, HbA1c is a biomarker of long-term glycemic control when compared with IFG and IGT, representing average blood glucose levels during the preceding two to three months. 28 However, our network meta-analysis may have several possible limitations. Firstly, the different frequencies, dosages, and routes of administration of pharmacological therapies may result in considerable heterogeneity. Secondly, differences in the inclusion criteria of participants and definition of the primary end-point events may influence the quality of evidence. Finally, study level data will be used rather than data on individuals.
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Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44 45 46 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y INTRODUCTION Type 2 diabetes mellitus (T2DM) is a chronic and complex disease, related to insulin secretory defects frequently on the background of insulin resistance; the progression of the disease is associated with genetic factors, metabolic stress, and inflammation. 1 The global prevalence of T2DM was estimated to be 463 million people in 2017. 2 People with T2DM are at elevated risk for chronic kidney disease, heart failure, atherosclerotic cardiovascular disease, polyneuropathy, cognitive impairment, anxiety disorder, and depression. [3] [4] [5] The term prediabetes is used to describe a blood glucose level higher than the normal range but below the cut-off value for T2DM. 6 Different glycemic measurements to define the prediabetic stage exist, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and elevated glycosylated haemoglobin A1c (HbA1c). 1 The International Diabetes Federation (IDF) estimated that, in 2017, approximately 352 million persons globally had IGT, which is projected to exceed half a billion people before 2045. 7 Hyperglycemia is a well described risk factor for all-cause mortality, total number of all-age deaths attributable to high fasting plasma was 6.5 million people in 2017, 8 with T2DM accounting for 1 million deaths. 9 Moreover, the economic burden of diabetes is large; in 2017, the American Diabetes Association (ADA) estimated the total economic costs attributable to diabetes in the U.S. to be $327 billion. 10, 11 Thus, there is an urgent need to address huge burden of this worldwide disease with a growing number of suffers. Early interventions for preventing T2DM are warranted. 10 Persons diagnosed with prediabetes are thought to be at increased risk for developing T2DM, the estimated incidence rate of diabetes among patients with prediabetes in the following 10 years exceeds one-third. 12 These people are ideal candidates for diabetes prevention efforts.
To prevent the progression of prediabetes to T2DM, an intensive behavioral lifestyle intervention program (e.g., medical nutrition therapy and physical activity) is recommended in the ADA guidelines. 13 Besides lifestyle modification, a variety of anti-diabetic agents (e.g., glucagon-like peptide (GLP)-1 analogues, metformin, and thiazolidinediones) have been investigated in clinical trials for diabetes prevention. These pharmacologic approaches with intrinsic glucose-lowering activity (e.g., improve the insulin resistance and preserve pancreaticβ -cell function) are recommended for glycemic treatment in patients with T2DM. 14 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   3 medications, only metformin therapy for diabetes prevention is recommended as an option for patients with prediabetes. 13 However, to date, whether other glucose-lowering agents should be considered in those patients or not has not yet to be clarified clearly, even though some findings of recent studies have demonstrated that these pharmacological agents could also exert benefits to prevent or delay the progression to T2DM. In addition, head-to-head comparisons of different anti-diabetic agents have rarely been performed by previous clinical trials. A network meta-analysis (NMA) method is able to combine direct and indirect evidence and assess comparative efficacy and safety of various interventions. [15] [16] [17] Therefore, we plan to conduct the systematic review and NMA to assess comparative effects and safety of various anti-diabetic medications in preventing T2DM in patients with prediabetes.
METHODS
Study design and registration
This systematic review protocol is reported in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines. 18, 19 This study will be performed in accordance with the PRISMA extension statements for NMA. 15
Eligibility criteria Population
Adults (older than 18 years) who have prediabetes will be eligible for inclusion. In this study, prediabetic state involves separate IFG, separate IGT, or both. Diagnostic criteria for prediabetes should be established and described in eligible trials.
Intervention and comparator
This study will investigate comparisons of anti-diabetic drugs versus another anti-diabetic agent, lifestyle interventions (diet, exercise, or both), placebo or no intervention. Anti-diabetic agents include alpha-glucosidase inhibitors (e.g., acarbose and voglibose), sulphonylureas (e.g., glipizide and glimepiride), meglitinide analogues (e.g., nateglinide), dipeptidyl-peptidase (DPP)-4 inhibitors (e.g., linagliptin and vildagliptin), glucagon-like peptide (GLP)-1 analogues (e.g., exenatide and liraglutide), biguanides (e.g., metformin), thiazolidinediones (e.g., rosiglitazone and pioglitazone), alone or in combination. In addition, studies using vitamins, traditional Chinese medicines, and alternative therapies will be excluded.
Outcomes
Type of studies
All randomized controlled trials (RCTs) comparing anti-diabetic drugs with another anti-diabetic agent, lifestyle interventions, placebo or no intervention for T2DM prevention in patients with prediabetes will be included in this study. Duration of intervention has to be with a minimum of 12 weeks. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Search strategy
Selection of studies
Data collection process
Assessment of methodological quality
The Cochrane risk of bias assessment tool will be used to assess risk of bias for individual studies. This method includes the following seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. 20 Each item will be classified into one of three categories as follows: unclear, high, or low risk. All discrepancies in quality assessment will be resolved after mutual agreement and discussion.
Data synthesis and statistical analysis
Initially, we will use a random-effects approach to pool effect estimates for all treatment comparisons in conventional pairwise meta-analyses. For categorical outcomes, the pooled 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 estimates as risk ratios (RRs) with 95% confidence intervals (CIs) will be reported. When data is available, to observe whether the effects of medications on diabetes prevention remain after intervention withdrawn, the pooled RRs for diabetes of the intervention and wash-out or follow-up periods, respectively, will be estimated. Continuous data will be reported as mean differences (MDs) with their respective 95% CIs. Statistical heterogeneity across trials will be examined using the I 2 statistic. The I 2 statistic of 75%, 50%, or 25% indicates high, moderate, or low heterogeneity, separately. 21 Then, a NMA will be conducted with a frequentist random-effects model. Local inconsistency between direct and indirect evidence within each closed loop will be assessed using a node-splitting test. 22, 23 In addition, a "design-by-treatment" model will be applied to evaluate the assumption of consistency in the whole network. 22 We will generate the surface under the cumulative ranking curve (SUCRA) to assess probabilities of interventions in superiority regarding efficacy and safety outcomes, with higher SUCRA values indicating better effects or safety. 24 The level of significance will be set at an alpha of 0.05. All analyses will be performed with Stata version 14.0 (StataCorp, College Station, TX).
Subgroup analyses
Where possible, analyses will be stratified by age (18-45 years and at least 45 years), gender, ethnicity, and BMI (25-29.9 kg/m 2 and ≥30 kg/m 2 ). Moreover, we will also perform subgroup analyses according to diagnostic criteria of prediabetes (IFG and IGT).
Publication bias
Quality of evidence
Patient and public involvement
Ethics and dissemination
DISCUSSION
This study is a comprehensive systematic review and NMA to compare a variety of anti-diabetic agents for preventing the development of T2DM in patients with prediabetes. Our study will provide a summary of available evidence concerning various anti-hyperglycemia agents for T2DM prevention in patients with prediabetic state, benefiting for clinicians and guideline-makers. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Previous relevant reviews and meta-analyses [27] [28] [29] only included clinical trials published before 2015. Importantly, recent large-scale RCTs (e.g., the ACE and IRIS trials) 30, 31 have provided substantial data with respect to this topic. Additionally, dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues are not involved in previous studies. It is essential to contain these commonly prescribed medications in multiple comparisons of glucose-lowering agents for the prevention of T2DM. Moreover, the influence of different diagnostic criteria for prediabetes (IFG and IGT) on the prevention efficacy of anti-diabetic agents remains uncertain. 28 Thus, we plan to conduct this study to investigate various anti-diabetic agents for diabetes prevention. The findings of our study will generate high quality recommendations regarding the optimal anti-diabetic agent to reduce risk of diabetes for patients with prediabetes. This study will combine data of all glucose-lowering drugs that have been tested for diabetes prevention by clinical trials. To develop better individualized strategies for diabetes prevention, intervention efficacy according to diagnostic criteria for prediabetes (IFG and IGT) will also be explored. However, our study may have several possible limitations. Firstly, the different frequencies, dosages, and routes of administration of pharmacological therapies may result in considerable heterogeneity. Secondly, differences in the inclusion criteria of participants and definition of the primary end-point events may influence the quality of evidence. Finally, study level data will be used rather than data on individuals.
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Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 4 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications 4
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Risk of bias in individual studies
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